Please assess the completion status of the following clinical trial:

Trial Title: Memantine Treatment Study of Pathological Gambling

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Pathological Gambling using the clinician-administered Structured Clinical Interview for Pathological Gambling (SCI-PG) (Grant et al., 2004);~* Gambling behavior within 2 weeks prior to enrollment;~* For women, negative results on a urine pregnancy test and stable use of a medically accepted form of contraception.~Exclusion Criteria:~* Infrequent gambling (i.e. less than one time per week) that does not meet DSM-IV criteria for PG;~* Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen;~* History of seizures;~* Myocardial infarction within 6 months;~* Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;~* A need for medication other than memantine with possible psychotropic effects or unfavorable interactions;~* Clinically significant suicidality;~* Current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders (Grant et al., 2005), except for nicotine dependence;~* Lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID;~* Current or recent (past 3 months) DSM-IV substance abuse or dependence;~* Positive urine drug screen at screening;~* Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline;~* Previous treatment with memantine;~* Treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- memantine (Type: EXPERIMENTAL): 10 to 30 mg/day memantine. The study consisted of 10 weeks of open-label memantine. All eligible study subjects were started at 10 mg/day for 2 weeks. The dose was increased to 20 mg/day after 2 weeks and then to 30 mg/day after 4 weeks unless remission of PG symptoms was attained at a lower dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).